Form 4: Ocuphire Pharma Director James S. J. Manuso Reports Changes in Beneficial Ownership

Director James S. J. Manuso reports acquisition and disposal of Ocuphire Pharma, Inc. stock and stock options.

Summary

• On June 11, 2024, James S. J. Manuso, a director of Ocuphire Pharma, Inc., reported changes in his beneficial ownership of the company's securities.
• Manuso acquired 41,143 shares of common stock at $0 and disposed of 132,037 shares.
• He also acquired 35,181 stock options with an exercise price of $1.72, exercisable starting June 11, 2024, and expiring on June 10, 2034.
• The restricted stock units vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.
• The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.
• Following these transactions, Manuso directly owns 35,181 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their ownership of company securities, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the transactions of a company director.

Key Dates